G9pharma co., LTD reported earnings results for the full year ended December 31, 2021. For the full year, the company reported net loss was KRW 37,256.82 million compared to KRW 45,054.88 million a year ago. Basic loss per share from continuing operations was KRW 10,314 compared to KRW 18,670 a year ago.

Diluted loss per share from continuing operations was KRW 10,314 compared to KRW 18,670 a year ago. Basic loss per share was KRW 10,314 compared to KRW 18,670 a year ago.